Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01)
The summary for the Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01): This Funding Opportunity Announcement (FOA) encourages applications to study the ethical, legal and societal issues (ELSI) of human genome research in African populations. Of particular interest are projects that propose focused bioethical, legal, and social science analyses of new or emerging issues. These applications should be for small, self-contained research projects.
Federal Grant Title: | Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-RM-12-005 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.310 |
CFDA Descriptions: | Trans-NIH Research Support |
Current Application Deadline: | Oct 31, 2012 |
Original Application Deadline: | Oct 29, 2012 |
Posted Date: | Jun 13, 2012 |
Creation Date: | Oct 26, 2012 |
Archive Date: | Nov 30, 2012 |
Total Program Funding: | $162,000 |
Maximum Federal Grant Award: | $50,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education - Private institutions of higher education - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Grant Announcement Contact
- NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
- • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)
- • Using Metabolomics to Investigate Biological Pathways and Networks (R01)
- • Assay Development for High Throughput Molecular Screening (R21)
- • Membrane Protein Production and Structure Determination (R01)
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...